Kintara Therapeutics Inc enrolls last patient in Phase 2 VAL-083 trial for recurrent glioblastoma multiforme proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
BEIJING and BRIDGEWATER, N.J., Jan. 29, 2021 /PRNewswire/ Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for GLR2007, for the treatment of patients with glioblastoma. GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor that Gan & Lee is developing for the treatment of advanced solid tumors including glioblastoma, an aggressive form of brain cancer with a low survival rate. Although considered a rare disease, glioblastoma is the most common brain and central nervous system (CNS) malignancy, accounting for 45.2% of malignant primary brain and CNS tumors
29 gennaio 2021 15:38
Fonte: Adnkronos
#salute-e-benessere
BEIJING and BRIDGEWATER, N.J., Jan. 29, 2021 /PRNewswire/ Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee) (Shanghai: 603087.SH), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for GLR2007, for the treatment of patients with glioblastoma. GLR2007 is a cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor that Gan & Lee is developing for the treatment of advanced solid tumors including glioblastoma, an aggressive form of brain cancer with a low survival rate. Although considered a rare disease, glioblastoma is the most common brain and central nervous system (CNS) malignancy, accounting for 45.2% of malignant primary brain and CNS tumors[1].
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 .
Ayala PharmaceuticalsJanuary 28, 2021 GMT
REHOVOT, Israel and WILMINGTON, Del., Jan. 28, 2021 (GLOBE NEWSWIRE) Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced the first patient dosed in the Phase 2 TENACITY clinical trial of its potent, selective small molecule AL101, for the treatment of patients with Notch-activated recurrent or metastatic (R/M) triple negative breast cancer (TNBC).
Share this article
Share this article
ENGLEWOOD CLIFFS, N.J., Jan. 26, 2021 /PRNewswire/ Enzychem Lifesciences (KOSDAQ: 183490), announced today that NASA s Human Research Program has awarded $150K in grant funding to conduct research on its lead compound EC-18, and how it impacts astronaut health and performance during future long-duration missions beyond low-Earth orbit. In this study, EC-18 will be investigated whether it can provide protection against both radiation and pathogen-induced tissue damage and inflammation.
The proposal was one of eight proposals selected by NASA, out of a total of 66 proposals submitted. Enzychem is conducting this study in collaboration with Dr. Cheryl Nickerson, professor at Arizona State University, who first demonstrated that some pathogenic microbes (Salmonella) exhibit enhanced pathogenicity in space and also pioneered use of spaceflight analog cell culture systems to develop 3-D biomimetic tissue models to study host-pathogen interactions